Literature DB >> 2642738

Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer.

C F Rochlitz1, G K Scott, J M Dodson, E Liu, C Dollbaum, H S Smith, C C Benz.   

Abstract

To test the hypothesis that ras activation is involved in the final stages of breast cancer progression, we analyzed tumor DNA derived from 60 different patients and extracted from 40 invasive primary breast tumors, seven lymph node and skin metastases, nine metastatic effusions, and five established breast cancer cell lines. The polymerase chain reaction technique was used to amplify DNA fragments containing Kirsten-(Ki-), Harvey-(Ha-), and N-ras codons 12, 13, and 61 which were then probed on slot-blots with labeled synthetic oligomers to detect nonconservative single base mutations. Activating mutations were found in one of 40 primary tumors (Ki-ras codon 13), zero of seven lymph node and skin metastases, one of nine metastatic effusions (Ki-ras codon 12), and two of five cell lines (Ki-ras codons 12 and 13). These results indicate that activating ras mutations are rarely involved in either the initiation or metastatic progression of human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2642738

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  31 in total

Review 1.  Demystified ... oncogenes.

Authors:  Y L Wallis; F Macdonald
Journal:  Mol Pathol       Date:  1999-04

Review 2.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

3.  Chemopreventive efficacy of stampidine in a murine breast cancer model.

Authors:  Kazim Sahin; Cemal Orhan; Ibrahim Hanifi Ozercan; Mehmet Tuzcu; Birsen Elibol; Taha Koray Sahin; Ulkan Kilic; Sanjive Qazi; Fatih Mehmet Uckun
Journal:  Expert Opin Ther Targets       Date:  2020-02-05       Impact factor: 6.902

4.  Loss of heterozygosity on the short arm of chromosome 17 is associated with high proliferative capacity and DNA aneuploidy in primary human breast cancer.

Authors:  L C Chen; A Neubauer; W Kurisu; F M Waldman; B M Ljung; W Goodson; E S Goldman; D Moore; M Balazs; E Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

5.  Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4.

Authors:  E H Radany; K Hong; S Kesharvarzi; E S Lander; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness.

Authors:  G Daniel Grass; Lauren B Tolliver; Momka Bratoeva; Bryan P Toole
Journal:  J Biol Chem       Date:  2013-07-25       Impact factor: 5.157

7.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

Authors:  Olga K Mirzoeva; Debopriya Das; Laura M Heiser; Sanchita Bhattacharya; Doris Siwak; Rina Gendelman; Nora Bayani; Nicholas J Wang; Richard M Neve; Yinghui Guan; Zhi Hu; Zachary Knight; Heidi S Feiler; Philippe Gascard; Bahram Parvin; Paul T Spellman; Kevan M Shokat; Andrew J Wyrobek; Mina J Bissell; Frank McCormick; Wen-Lin Kuo; Gordon B Mills; Joe W Gray; W Michael Korn
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Ha-ras rare alleles in breast cancer susceptibility.

Authors:  K Conway; S Edmiston; D B Fried; B S Hulka; P A Garrett; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

9.  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Authors:  Joseph A Sparano; Stacy Moulder; Aslamuzzaman Kazi; Domenico Coppola; Abdissa Negassa; Linda Vahdat; Tianhong Li; Christine Pellegrino; Susan Fineberg; Pam Munster; Mokenge Malafa; David Lee; Shira Hoschander; Una Hopkins; Dawn Hershman; John J Wright; Celina Kleer; Sofia Merajver; Said M Sebti
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

10.  Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.

Authors:  Radharani Gollamudi; Mohammad H Ghalib; Kavita K Desai; Imran Chaudhary; Benny Wong; Mark Einstein; Matthew Coffey; George M Gill; Karl Mettinger; John M Mariadason; Sridhar Mani; Sanjay Goel
Journal:  Invest New Drugs       Date:  2009-07-02       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.